Cytokinetics, Incorporated
Hedge Funds Holdings
Last updated:
Cytokinetics, Incorporated‘s stocks are currently a part of 248 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 97.26M shares of Cytokinetics, Incorporated. Compared to the previous quarter, the number fell by -7.53% or -7.92M shares fewer. As for the holding position changes, 40.73% (101) of current hedge fund investors increased the number of shares held, 30.65% (76) of current holders sold a part of the shares held, and 9.27% (23) closed the holdings completely. 36 hedge funds are new holders of Cytokinetics, Incorporated stock in Q3 2022, it is 14.52% of total holders.
Hedge funds holding Cytokinetics, Incorporated (Q4 2017 – Q3 2022)
| Q4 2017 | 130 |
|---|---|
| Q1 2018 | 121 |
| Q2 2018 | 121 |
| Q3 2018 | 115 |
| Q4 2018 | 129 |
| Q1 2019 | 131 |
| Q2 2019 | 130 |
| Q3 2019 | 143 |
| Q4 2019 | 140 |
| Q1 2020 | 145 |
| Q2 2020 | 157 |
| Q3 2020 | 179 |
| Q4 2020 | 174 |
| Q1 2021 | 187 |
| Q2 2021 | 185 |
| Q3 2021 | 206 |
| Q4 2021 | 244 |
| Q1 2022 | 229 |
| Q2 2022 | 255 |
| Q3 2022 | 248 |
Hedge funds changes in Cytokinetics, Incorporated positions (Q4 2017 – Q3 2022)
| Q4 2017 | 22 | 43 | 45 | 18 | 2 |
|---|---|---|---|---|---|
| Q1 2018 | 15 | 37 | 41 | 20 | 8 |
| Q2 2018 | 19 | 39 | 37 | 18 | 8 |
| Q3 2018 | 11 | 47 | 33 | 16 | 8 |
| Q4 2018 | 19 | 53 | 36 | 6 | 15 |
| Q1 2019 | 14 | 64 | 25 | 12 | 16 |
| Q2 2019 | 18 | 66 | 23 | 17 | 6 |
| Q3 2019 | 19 | 55 | 37 | 6 | 26 |
| Q4 2019 | 26 | 51 | 40 | 23 | 0 |
| Q1 2020 | 23 | 58 | 40 | 16 | 8 |
| Q2 2020 | 28 | 61 | 49 | 16 | 3 |
| Q3 2020 | 41 | 87 | 35 | 20 | -4 |
| Q4 2020 | 37 | 59 | 57 | 41 | -20 |
| Q1 2021 | 29 | 62 | 63 | 16 | 17 |
| Q2 2021 | 21 | 67 | 65 | 23 | 9 |
| Q3 2021 | 50 | 95 | 42 | 27 | -8 |
| Q4 2021 | 51 | 82 | 78 | 10 | 23 |
| Q1 2022 | 18 | 98 | 82 | 32 | -1 |
| Q2 2022 | 49 | 104 | 70 | 19 | 13 |
| Q3 2022 | 36 | 101 | 76 | 23 | 12 |
Hedge funds changes in Cytokinetics, Incorporated stock options (Q4 2017 – Q3 2022)
| Q4 2017 | 1,236,000 | 1,990,000 |
|---|---|---|
| Q1 2018 | 973,000 | 1,100,000 |
| Q2 2018 | 591,000 | 731,000 |
| Q3 2018 | 917,000 | 875,000 |
| Q4 2018 | 314,000 | 555,000 |
| Q1 2019 | 607,000 | 436,000 |
| Q2 2019 | 7,068,000 | 917,000 |
| Q3 2019 | 3,929,000 | 381,000 |
| Q4 2019 | 2,586,000 | 2,975,000 |
| Q1 2020 | 11,729,000 | 11,194,000 |
| Q2 2020 | 5,329,000 | 7,928,000 |
| Q3 2020 | 62,699,000 | 50,402,000 |
| Q4 2020 | 14,083,000 | 6,653,000 |
| Q1 2021 | 6,257,000 | 3,235,000 |
| Q2 2021 | 10,007,000 | 5,602,000 |
| Q3 2021 | 16,689,000 | 5,690,000 |
| Q4 2021 | 9,787,000 | 5,506,000 |
| Q1 2022 | 12,715,000 | 5,412,000 |
| Q2 2022 | 33,387,000 | 5,950,000 |
| Q3 2022 | 46,044,000 | 6,971,000 |